Kenneth M Borow, John R Nelson, R Preston Mason. Atherosclerosis 2015
Times Cited: 102
Times Cited: 102
Times Cited
Times Co-cited
Similarity
Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis.
Mitsuhiro Yokoyama, Hideki Origasa, Masunori Matsuzaki, Yuji Matsuzawa, Yasushi Saito, Yuichi Ishikawa, Shinichi Oikawa, Jun Sasaki, Hitoshi Hishida, Hiroshige Itakura,[...]. Lancet 2007
Mitsuhiro Yokoyama, Hideki Origasa, Masunori Matsuzaki, Yuji Matsuzawa, Yasushi Saito, Yuichi Ishikawa, Shinichi Oikawa, Jun Sasaki, Hitoshi Hishida, Hiroshige Itakura,[...]. Lancet 2007
58
Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
Deepak L Bhatt, P Gabriel Steg, Michael Miller, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum, Ralph T Doyle, Rebecca A Juliano, Lixia Jiao, Craig Granowitz,[...]. N Engl J Med 2019
Deepak L Bhatt, P Gabriel Steg, Michael Miller, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum, Ralph T Doyle, Rebecca A Juliano, Lixia Jiao, Craig Granowitz,[...]. N Engl J Med 2019
43
Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study).
Christie M Ballantyne, Harold E Bays, John J Kastelein, Evan Stein, Jonathan L Isaacsohn, Rene A Braeckman, Paresh N Soni. Am J Cardiol 2012
Christie M Ballantyne, Harold E Bays, John J Kastelein, Evan Stein, Jonathan L Isaacsohn, Rene A Braeckman, Paresh N Soni. Am J Cardiol 2012
38
Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] trial).
Harold E Bays, Christie M Ballantyne, John J Kastelein, Jonathan L Isaacsohn, Rene A Braeckman, Paresh N Soni. Am J Cardiol 2011
Harold E Bays, Christie M Ballantyne, John J Kastelein, Jonathan L Isaacsohn, Rene A Braeckman, Paresh N Soni. Am J Cardiol 2011
35
Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events.
Dariush Mozaffarian, Jason H Y Wu. J Am Coll Cardiol 2011
Dariush Mozaffarian, Jason H Y Wu. J Am Coll Cardiol 2011
26
Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies.
Harold E Bays, Christie M Ballantyne, Rene A Braeckman, William G Stirtan, Paresh N Soni. Am J Cardiovasc Drugs 2013
Harold E Bays, Christie M Ballantyne, Rene A Braeckman, William G Stirtan, Paresh N Soni. Am J Cardiovasc Drugs 2013
27
A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins.
Tetsu Watanabe, Kaoru Ando, Hyuma Daidoji, Yoichiro Otaki, Shigeo Sugawara, Motoyuki Matsui, Eiichiro Ikeno, Osamu Hirono, Hiroshi Miyawaki, Yoshinori Yashiro,[...]. J Cardiol 2017
Tetsu Watanabe, Kaoru Ando, Hyuma Daidoji, Yoichiro Otaki, Shigeo Sugawara, Motoyuki Matsui, Eiichiro Ikeno, Osamu Hirono, Hiroshi Miyawaki, Yoshinori Yashiro,[...]. J Cardiol 2017
33
Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.
Louise Bowman, Marion Mafham, Karl Wallendszus, Will Stevens, Georgina Buck, Jill Barton, Kevin Murphy, Theingi Aung, Richard Haynes, Jolyon Cox,[...]. N Engl J Med 2018
Louise Bowman, Marion Mafham, Karl Wallendszus, Will Stevens, Georgina Buck, Jill Barton, Kevin Murphy, Theingi Aung, Richard Haynes, Jolyon Cox,[...]. N Engl J Med 2018
22
Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks: Meta-analysis of 10 Trials Involving 77 917 Individuals.
Theingi Aung, Jim Halsey, Daan Kromhout, Hertzel C Gerstein, Roberto Marchioli, Luigi Tavazzi, Johanna M Geleijnse, Bernhard Rauch, Andrew Ness, Pilar Galan,[...]. JAMA Cardiol 2018
Theingi Aung, Jim Halsey, Daan Kromhout, Hertzel C Gerstein, Roberto Marchioli, Luigi Tavazzi, Johanna M Geleijnse, Bernhard Rauch, Andrew Ness, Pilar Galan,[...]. JAMA Cardiol 2018
21
Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma.
Ryo Nishio, Toshiro Shinke, Hiromasa Otake, Masayuki Nakagawa, Ryoji Nagoshi, Takumi Inoue, Amane Kozuki, Hirotoshi Hariki, Tsuyoshi Osue, Yu Taniguchi,[...]. Atherosclerosis 2014
Ryo Nishio, Toshiro Shinke, Hiromasa Otake, Masayuki Nakagawa, Ryoji Nagoshi, Takumi Inoue, Amane Kozuki, Hirotoshi Hariki, Tsuyoshi Osue, Yu Taniguchi,[...]. Atherosclerosis 2014
27
Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review.
Terry A Jacobson, Sara B Glickstein, Jonathan D Rowe, Paresh N Soni. J Clin Lipidol 2012
Terry A Jacobson, Sara B Glickstein, Jonathan D Rowe, Paresh N Soni. J Clin Lipidol 2012
20
Eicosapentaenoic Acid Inhibits Oxidation of ApoB-containing Lipoprotein Particles of Different Size In Vitro When Administered Alone or in Combination With Atorvastatin Active Metabolite Compared With Other Triglyceride-lowering Agents.
R Preston Mason, Samuel C R Sherratt, Robert F Jacob. J Cardiovasc Pharmacol 2016
R Preston Mason, Samuel C R Sherratt, Robert F Jacob. J Cardiovasc Pharmacol 2016
57
Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes.
R Preston Mason, Robert F Jacob, Sandeep Shrivastava, Samuel C R Sherratt, Amitabha Chattopadhyay. Biochim Biophys Acta 2016
R Preston Mason, Robert F Jacob, Sandeep Shrivastava, Samuel C R Sherratt, Amitabha Chattopadhyay. Biochim Biophys Acta 2016
27
Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque inflammation and increased stability.
Abbie L Cawood, Ren Ding, Frances L Napper, Ruth H Young, Jennifer A Williams, Matthew J A Ward, Ola Gudmundsen, Runar Vige, Simon P K Payne, Shu Ye,[...]. Atherosclerosis 2010
Abbie L Cawood, Ren Ding, Frances L Napper, Ruth H Young, Jennifer A Williams, Matthew J A Ward, Ola Gudmundsen, Runar Vige, Simon P K Payne, Shu Ye,[...]. Atherosclerosis 2010
19
Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial.
Deepak L Bhatt, Ph Gabriel Steg, Eliot A Brinton, Terry A Jacobson, Michael Miller, Jean-Claude Tardif, Steven B Ketchum, Ralph T Doyle, Sabina A Murphy, Paresh N Soni,[...]. Clin Cardiol 2017
Deepak L Bhatt, Ph Gabriel Steg, Eliot A Brinton, Terry A Jacobson, Michael Miller, Jean-Claude Tardif, Steven B Ketchum, Ralph T Doyle, Sabina A Murphy, Paresh N Soni,[...]. Clin Cardiol 2017
19
Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer.
JoAnn E Manson, Nancy R Cook, I-Min Lee, William Christen, Shari S Bassuk, Samia Mora, Heike Gibson, Christine M Albert, David Gordon, Trisha Copeland,[...]. N Engl J Med 2019
JoAnn E Manson, Nancy R Cook, I-Min Lee, William Christen, Shari S Bassuk, Samia Mora, Heike Gibson, Christine M Albert, David Gordon, Trisha Copeland,[...]. N Engl J Med 2019
19
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia.
Jackie Bosch, Hertzel C Gerstein, Gilles R Dagenais, Rafael Díaz, Leanne Dyal, Hyejung Jung, Aldo P Maggiono, Jeffrey Probstfield, Ambady Ramachandran, Matthew C Riddle,[...]. N Engl J Med 2012
Jackie Bosch, Hertzel C Gerstein, Gilles R Dagenais, Rafael Díaz, Leanne Dyal, Hyejung Jung, Aldo P Maggiono, Jeffrey Probstfield, Ambady Ramachandran, Matthew C Riddle,[...]. N Engl J Med 2012
18
Effects of extended-release niacin with laropiprant in high-risk patients.
Martin J Landray, Richard Haynes, Jemma C Hopewell, Sarah Parish, Theingi Aung, Joseph Tomson, Karl Wallendszus, Martin Craig, Lixin Jiang, Rory Collins,[...]. N Engl J Med 2014
Martin J Landray, Richard Haynes, Jemma C Hopewell, Sarah Parish, Theingi Aung, Joseph Tomson, Karl Wallendszus, Martin Craig, Lixin Jiang, Rory Collins,[...]. N Engl J Med 2014
18
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Christopher P Cannon, Michael A Blazing, Robert P Giugliano, Amy McCagg, Jennifer A White, Pierre Theroux, Harald Darius, Basil S Lewis, Ton Oude Ophuis, J Wouter Jukema,[...]. N Engl J Med 2015
Christopher P Cannon, Michael A Blazing, Robert P Giugliano, Amy McCagg, Jennifer A White, Pierre Theroux, Harald Darius, Basil S Lewis, Ton Oude Ophuis, J Wouter Jukema,[...]. N Engl J Med 2015
17
Relationships between plasma fatty acid composition and coronary artery disease.
Hiroshige Itakura, Mitsuhiro Yokoyama, Masunori Matsuzaki, Yasushi Saito, Hideki Origasa, Yuichi Ishikawa, Shinichi Oikawa, Jun Sasaki, Hitoshi Hishida, Toru Kita,[...]. J Atheroscler Thromb 2011
Hiroshige Itakura, Mitsuhiro Yokoyama, Masunori Matsuzaki, Yasushi Saito, Hideki Origasa, Yuichi Ishikawa, Shinichi Oikawa, Jun Sasaki, Hitoshi Hishida, Toru Kita,[...]. J Atheroscler Thromb 2011
17
Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism.
R Preston Mason, Robert F Jacob. Biochim Biophys Acta 2015
R Preston Mason, Robert F Jacob. Biochim Biophys Acta 2015
44
Effects of combination lipid therapy in type 2 diabetes mellitus.
Henry N Ginsberg, Marshall B Elam, Laura C Lovato, John R Crouse, Lawrence A Leiter, Peter Linz, William T Friedewald, John B Buse, Hertzel C Gerstein, Jeffrey Probstfield,[...]. N Engl J Med 2010
Henry N Ginsberg, Marshall B Elam, Laura C Lovato, John R Crouse, Lawrence A Leiter, Peter Linz, William T Friedewald, John B Buse, Hertzel C Gerstein, Jeffrey Probstfield,[...]. N Engl J Med 2010
17
Unmet Need for Adjunctive Dyslipidemia Therapy in Hypertriglyceridemia Management.
Om P Ganda, Deepak L Bhatt, R Preston Mason, Michael Miller, William E Boden. J Am Coll Cardiol 2018
Om P Ganda, Deepak L Bhatt, R Preston Mason, Michael Miller, William E Boden. J Am Coll Cardiol 2018
17
Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association.
Michael Miller, Neil J Stone, Christie Ballantyne, Vera Bittner, Michael H Criqui, Henry N Ginsberg, Anne Carol Goldberg, William James Howard, Marc S Jacobson, Penny M Kris-Etherton,[...]. Circulation 2011
Michael Miller, Neil J Stone, Christie Ballantyne, Vera Bittner, Michael H Criqui, Henry N Ginsberg, Anne Carol Goldberg, William James Howard, Marc S Jacobson, Penny M Kris-Etherton,[...]. Circulation 2011
16
Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: Rationale and design of the STRENGTH trial.
Stephen J Nicholls, A Michael Lincoff, Dianna Bash, Christie M Ballantyne, Philip J Barter, Michael H Davidson, John J P Kastelein, Wolfgang Koenig, Darren K McGuire, Dariush Mozaffarian,[...]. Clin Cardiol 2018
Stephen J Nicholls, A Michael Lincoff, Dianna Bash, Christie M Ballantyne, Philip J Barter, Michael H Davidson, John J P Kastelein, Wolfgang Koenig, Darren K McGuire, Dariush Mozaffarian,[...]. Clin Cardiol 2018
16
n-3 fatty acids and cardiovascular events after myocardial infarction.
Daan Kromhout, Erik J Giltay, Johanna M Geleijnse. N Engl J Med 2010
Daan Kromhout, Erik J Giltay, Johanna M Geleijnse. N Engl J Med 2010
15
Residual macrovascular risk in 2013: what have we learned?
Jean-Charles Fruchart, Jean Davignon, Michel P Hermans, Khalid Al-Rubeaan, Pierre Amarenco, Gerd Assmann, Philip Barter, John Betteridge, Eric Bruckert, Ada Cuevas,[...]. Cardiovasc Diabetol 2014
Jean-Charles Fruchart, Jean Davignon, Michel P Hermans, Khalid Al-Rubeaan, Pierre Amarenco, Gerd Assmann, Philip Barter, John Betteridge, Eric Bruckert, Ada Cuevas,[...]. Cardiovasc Diabetol 2014
15
Effects of the Addition of Eicosapentaenoic Acid to Strong Statin Therapy on Inflammatory Cytokines and Coronary Plaque Components Assessed by Integrated Backscatter Intravascular Ultrasound.
Toshiyuki Niki, Tetsuzo Wakatsuki, Koji Yamaguchi, Yoshio Taketani, Hiroyasu Oeduka, Kenya Kusunose, Takayuki Ise, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki,[...]. Circ J 2016
Toshiyuki Niki, Tetsuzo Wakatsuki, Koji Yamaguchi, Yoshio Taketani, Hiroyasu Oeduka, Kenya Kusunose, Takayuki Ise, Takashi Iwase, Hirotsugu Yamada, Takeshi Soeki,[...]. Circ J 2016
28
Potential benefits of eicosapentaenoic acid on atherosclerotic plaques.
J R Nelson, O Wani, H T May, M Budoff. Vascul Pharmacol 2017
J R Nelson, O Wani, H T May, M Budoff. Vascul Pharmacol 2017
34
Effect of Vascepa (icosapent ethyl) on progression of coronary atherosclerosis in patients with elevated triglycerides (200-499 mg/dL) on statin therapy: Rationale and design of the EVAPORATE study.
Matthew Budoff, J Brent Muhlestein, Viet T Le, Heidi T May, Sion Roy, John R Nelson. Clin Cardiol 2018
Matthew Budoff, J Brent Muhlestein, Viet T Le, Heidi T May, Sion Roy, John R Nelson. Clin Cardiol 2018
30
Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
Deepak L Bhatt, Ph Gabriel Steg, Michael Miller, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum, Ralph T Doyle, Rebecca A Juliano, Lixia Jiao, Craig Granowitz,[...]. J Am Coll Cardiol 2019
Deepak L Bhatt, Ph Gabriel Steg, Michael Miller, Eliot A Brinton, Terry A Jacobson, Steven B Ketchum, Ralph T Doyle, Rebecca A Juliano, Lixia Jiao, Craig Granowitz,[...]. J Am Coll Cardiol 2019
15
Emerging Mechanisms of Cardiovascular Protection for the Omega-3 Fatty Acid Eicosapentaenoic Acid.
R Preston Mason, Peter Libby, Deepak L Bhatt. Arterioscler Thromb Vasc Biol 2020
R Preston Mason, Peter Libby, Deepak L Bhatt. Arterioscler Thromb Vasc Biol 2020
15
Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
John J P Kastelein, Kevin C Maki, Andrey Susekov, Marat Ezhov, Borge G Nordestgaard, Ben N Machielse, Douglas Kling, Michael H Davidson. J Clin Lipidol 2014
John J P Kastelein, Kevin C Maki, Andrey Susekov, Marat Ezhov, Borge G Nordestgaard, Ben N Machielse, Douglas Kling, Michael H Davidson. J Clin Lipidol 2014
14
OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction.
Bernhard Rauch, Rudolf Schiele, Steffen Schneider, Frank Diller, Norbert Victor, Helmut Gohlke, Martin Gottwik, Gerhard Steinbeck, Ulrike Del Castillo, Rudolf Sack,[...]. Circulation 2010
Bernhard Rauch, Rudolf Schiele, Steffen Schneider, Frank Diller, Norbert Victor, Helmut Gohlke, Martin Gottwik, Gerhard Steinbeck, Ulrike Del Castillo, Rudolf Sack,[...]. Circulation 2010
14
Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis.
Melissa Y Wei, Terry A Jacobson. Curr Atheroscler Rep 2011
Melissa Y Wei, Terry A Jacobson. Curr Atheroscler Rep 2011
14
Administration of highly purified eicosapentaenoic acid to statin-treated diabetic patients further improves vascular function.
Junko Sasaki, Takashi Miwa, Masato Odawara. Endocr J 2012
Junko Sasaki, Takashi Miwa, Masato Odawara. Endocr J 2012
58
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on plasma apolipoprotein C-III levels in patients from the MARINE and ANCHOR studies.
Christie M Ballantyne, Harold E Bays, Rene A Braeckman, Sephy Philip, William G Stirtan, Ralph T Doyle, Paresh N Soni, Rebecca A Juliano. J Clin Lipidol 2016
Christie M Ballantyne, Harold E Bays, Rene A Braeckman, Sephy Philip, William G Stirtan, Ralph T Doyle, Paresh N Soni, Rebecca A Juliano. J Clin Lipidol 2016
43
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
William E Boden, Jeffrey L Probstfield, Todd Anderson, Bernard R Chaitman, Patrice Desvignes-Nickens, Kent Koprowicz, Ruth McBride, Koon Teo, William Weintraub. N Engl J Med 2011
William E Boden, Jeffrey L Probstfield, Todd Anderson, Bernard R Chaitman, Patrice Desvignes-Nickens, Kent Koprowicz, Ruth McBride, Koon Teo, William Weintraub. N Engl J Med 2011
14
Remnant cholesterol as a causal risk factor for ischemic heart disease.
Anette Varbo, Marianne Benn, Anne Tybjærg-Hansen, Anders B Jørgensen, Ruth Frikke-Schmidt, Børge G Nordestgaard. J Am Coll Cardiol 2013
Anette Varbo, Marianne Benn, Anne Tybjærg-Hansen, Anders B Jørgensen, Ruth Frikke-Schmidt, Børge G Nordestgaard. J Am Coll Cardiol 2013
13
Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.
Luigi Tavazzi, Aldo P Maggioni, Roberto Marchioli, Simona Barlera, Maria Grazia Franzosi, Roberto Latini, Donata Lucci, Gian Luigi Nicolosi, Maurizio Porcu, Gianni Tognoni. Lancet 2008
Luigi Tavazzi, Aldo P Maggioni, Roberto Marchioli, Simona Barlera, Maria Grazia Franzosi, Roberto Latini, Donata Lucci, Gian Luigi Nicolosi, Maurizio Porcu, Gianni Tognoni. Lancet 2008
13
Loss-of-function mutations in APOC3, triglycerides, and coronary disease.
Jacy Crosby, Gina M Peloso, Paul L Auer, David R Crosslin, Nathan O Stitziel, Leslie A Lange, Yingchang Lu, Zheng-zheng Tang, He Zhang, George Hindy,[...]. N Engl J Med 2014
Jacy Crosby, Gina M Peloso, Paul L Auer, David R Crosslin, Nathan O Stitziel, Leslie A Lange, Yingchang Lu, Zheng-zheng Tang, He Zhang, George Hindy,[...]. N Engl J Med 2014
13
Triglycerides and Triglyceride-Rich Lipoproteins in the Causal Pathway of Cardiovascular Disease.
Matthew Budoff. Am J Cardiol 2016
Matthew Budoff. Am J Cardiol 2016
16
Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial.
Michael Miller, Christopher P Cannon, Sabina A Murphy, Jie Qin, Kausik K Ray, Eugene Braunwald. J Am Coll Cardiol 2008
Michael Miller, Christopher P Cannon, Sabina A Murphy, Jie Qin, Kausik K Ray, Eugene Braunwald. J Am Coll Cardiol 2008
13
Eicosapentaenoic acid and docosahexaenoic acid have distinct membrane locations and lipid interactions as determined by X-ray diffraction.
Samuel C R Sherratt, R Preston Mason. Chem Phys Lipids 2018
Samuel C R Sherratt, R Preston Mason. Chem Phys Lipids 2018
25
New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease.
R Preston Mason. Curr Atheroscler Rep 2019
R Preston Mason. Curr Atheroscler Rep 2019
24
Loss-of-function mutations in APOC3 and risk of ischemic vascular disease.
Anders Berg Jørgensen, Ruth Frikke-Schmidt, Børge G Nordestgaard, Anne Tybjærg-Hansen. N Engl J Med 2014
Anders Berg Jørgensen, Ruth Frikke-Schmidt, Børge G Nordestgaard, Anne Tybjærg-Hansen. N Engl J Med 2014
12
Administration of high dose eicosapentaenoic acid enhances anti-inflammatory properties of high-density lipoprotein in Japanese patients with dyslipidemia.
Nobuaki Tanaka, Tatsuro Ishida, Manabu Nagao, Takeshige Mori, Tomoko Monguchi, Maki Sasaki, Kenta Mori, Kensuke Kondo, Hideto Nakajima, Tomoyuki Honjo,[...]. Atherosclerosis 2014
Nobuaki Tanaka, Tatsuro Ishida, Manabu Nagao, Takeshige Mori, Tomoko Monguchi, Maki Sasaki, Kenta Mori, Kensuke Kondo, Hideto Nakajima, Tomoyuki Honjo,[...]. Atherosclerosis 2014
23
Icosapent ethyl, a pure EPA omega-3 fatty acid: effects on plasma and red blood cell fatty acids in patients with very high triglyceride levels (results from the MARINE study).
Rene A Braeckman, Mehar S Manku, Harold E Bays, William G Stirtan, Paresh N Soni. Prostaglandins Leukot Essent Fatty Acids 2013
Rene A Braeckman, Mehar S Manku, Harold E Bays, William G Stirtan, Paresh N Soni. Prostaglandins Leukot Essent Fatty Acids 2013
32
Icosapent ethyl (eicosapentaenoic acid ethyl ester): Effects on remnant-like particle cholesterol from the MARINE and ANCHOR studies.
Christie M Ballantyne, Harold E Bays, Sephy Philip, Ralph T Doyle, Rene A Braeckman, William G Stirtan, Paresh N Soni, Rebecca A Juliano. Atherosclerosis 2016
Christie M Ballantyne, Harold E Bays, Sephy Philip, Ralph T Doyle, Rene A Braeckman, William G Stirtan, Paresh N Soni, Rebecca A Juliano. Atherosclerosis 2016
42
Eicosapentaenoic acid inhibits oxidation of high density lipoprotein particles in a manner distinct from docosahexaenoic acid.
Samuel C R Sherratt, R Preston Mason. Biochem Biophys Res Commun 2018
Samuel C R Sherratt, R Preston Mason. Biochem Biophys Res Commun 2018
66
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.